Get the Stockscreener App
0.7499
8.65%
-0.071
Eyenovia Inc stock is currently priced at $0.7499, with a 24-hour trading volume of 1.01M.
It has seen a -8.65% decreased in the last 24 hours and a +39.05% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.8403 pivot point. If it approaches the $0.7403 support level, significant changes may occur.
Previous Close:
$0.8209
Open:
$0.8221
24h Volume:
1.01M
Market Cap:
$40.40M
Revenue:
-
Net Income/Loss:
$-27.26M
P/E Ratio:
-1.0868
EPS:
-0.69
Net Cash Flow:
$-27.81M
1W Performance:
-2.77%
1M Performance:
+39.05%
6M Performance:
-44.04%
1Y Performance:
-78.99%
1D Range:
$0.7498
$0.8699
52W Range:
$0.501
$3.59
Eyenovia Inc Stock (EYEN) Company Profile
Name
Eyenovia Inc
Sector
Industry
Phone
917-289-1117
Address
501 Fifth Avenue, Suite 1404, New York, NY
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-21 | Initiated | Northland Capital | Outperform |
| Feb-03-20 | Downgrade | Oppenheimer | Outperform → Perform |
Eyenovia Inc Stock (EYEN) Latest News
Eyenovia, Inc. (NASDAQ:EYEN) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
EYEN Stock Sees Surge of Approximately 22.54% in Last Five Days – Knox Daily - Knox Daily
Knox Daily
Eyenovia (NASDAQ:EYEN) Given Buy Rating at HC Wainwright - MarketBeat
MarketBeat
Earnings call: Eyenovia reports Q1 2024 results, focuses on product pipeline - Investing.com Australia
Investing.com Australia
Earnings call: Eyenovia reports Q1 2024 results, focuses on product pipeline - Investing.com South Africa
Investing.com South Africa
Earnings call: Eyenovia reports Q1 2024 results, focuses on product pipeline By Investing.com - Investing.com
Investing.com
Eyenovia Inc Stock (EYEN) Financials Data
Eyenovia Inc (EYEN) Net Income 2024
EYEN net income (TTM) was -$27.26 million for the quarter ending December 31, 2023, a +2.68% increase year-over-year.
Eyenovia Inc (EYEN) Cash Flow 2024
EYEN recorded a free cash flow (TTM) of -$27.81 million for the quarter ending December 31, 2023, a -7.03% decrease year-over-year.
Eyenovia Inc (EYEN) Earnings per Share 2024
EYEN earnings per share (TTM) was -$0.65 for the quarter ending December 31, 2023, a +22.62% growth year-over-year.
Eyenovia Inc Stock (EYEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grant Stuart M. | 10% Owner |
Mar 19 '24 |
Buy |
1.23 |
50,000 |
61,500 |
5,330,715 |
| Grant Stuart M. | 10% Owner |
Mar 08 '24 |
Buy |
1.58 |
10,717 |
16,911 |
5,280,715 |
| Rowe Michael M | Chief Executive Officer |
Dec 04 '23 |
Buy |
1.36 |
4,890 |
6,650 |
32,927 |
| Strahlman Ellen R | Director |
Sep 29 '23 |
Buy |
1.68 |
4,820 |
8,098 |
75,113 |
| Rowe Michael M | Chief Executive Officer |
Sep 19 '23 |
Buy |
1.66 |
1,400 |
2,324 |
28,037 |
| Rowe Michael M | Chief Executive Officer |
Sep 15 '23 |
Buy |
1.75 |
1,137 |
1,990 |
26,637 |
| Grant Stuart M. | 10% Owner |
Aug 17 '23 |
Buy |
1.87 |
30,000 |
56,100 |
5,269,998 |
| Grant Stuart M. | 10% Owner |
Aug 16 '23 |
Buy |
1.91 |
45,000 |
85,815 |
5,239,998 |
| GANDOLFO JOHN P | Chief Financial Officer |
May 31 '23 |
Buy |
2.79 |
2,000 |
5,580 |
8,000 |
| MATHER CHARLES E IV | Director |
May 26 '23 |
Buy |
2.49 |
3,000 |
7,470 |
77,544 |
About Eyenovia Inc
Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
0.77%
1.20%
Cap:
|
Volume (24h):